Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
poor enrollment
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study objective is to determine whether a single intra-articular dose of an anti-inflammatory (Toradol) will reduce the need for other analgesic medications and, if so, how long the benefits will last.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Toradol injection | Experimental | 3-ml solution that contains 2 ml of normal saline and 1 ml of Toradol, 30 mg, will be infused into the affected joint. |
|
| Oral NSAID | Active Comparator | 800mg Motrin will be administered. (non-steroidal anti-inflammatory drug (NSAID)) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Toradol | Drug | 3-ml solution that contains 2 ml of normal saline and 1 ml of Toradol, 30 mg, will be infused into the affected joint. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Pain Medication Usage for Breakthrough Pain | 72 hours | |
| Pain Level as Assessed by a Visual Analogue Scale | 72 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Pain Medication Usage for Breakthrough Pain | The number of pills will be reported | 1 week post treatment |
| Pain Medication Usage for Breakthrough Pain | The number of pills will be reported |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Kimberly A Chambers, MD | The University of Texas Health Science Center, Houston | Principal Investigator |
Not provided
| ID | Term |
|---|---|
| D020911 | Ketorolac Tromethamine |
| D020910 | Ketorolac |
| D000894 | Anti-Inflammatory Agents, Non-Steroidal |
| D007052 | Ibuprofen |
| ID | Term |
|---|---|
| D007213 | Indomethacin |
| D007211 | Indoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Oral NSAID | Drug | 800mg Motrin will be administered. (non-steroidal anti-inflammatory drug (NSAID)) |
|
|
| 2 weeks post treatment |
| Pain Medication Usage for Breakthrough Pain | The number of pills will be reported | 3 weeks post treatment |
| Pain Medication Usage for Breakthrough Pain | The number of pills will be reported | 4 weeks post treatment |
| Pain Level as Assessed by a Visual Analogue Scale | 1 week post treatment |
| Pain Level as Assessed by a Visual Analogue Scale | 2 weeks post treatment |
| Pain Level as Assessed by a Visual Analogue Scale | 3 weeks post treatment |
| Pain Level as Assessed by a Visual Analogue Scale | 4 weeks post treatment |
| Number of Participants who had a second visit to a Emergency Department or Clinic | 4 weeks |
| D006571 | Heterocyclic Compounds |
| D018712 | Analgesics, Non-Narcotic |
| D000700 | Analgesics |
| D018689 | Sensory System Agents |
| D018373 | Peripheral Nervous System Agents |
| D045505 | Physiological Effects of Drugs |
| D020228 | Pharmacologic Actions |
| D020164 | Chemical Actions and Uses |
| D000893 | Anti-Inflammatory Agents |
| D045506 | Therapeutic Uses |
| D018501 | Antirheumatic Agents |
| D010666 | Phenylpropionates |
| D000146 | Acids, Carbocyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |